Adversarial Injection · Abemaciclib (Verzenio; CAS 1231929-97-7; N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine [MW 506.59 g/mol; C27H32F2N8; difluorophenyl-benzimidazole-aminopyrimidine scaffold [FIRST imidazole-fused benzimidazole bicyclic core in Glyphward CDK4/6 portfolio; palbociclib uses pyrido[2,3-d]pyrimidinone; ribociclib uses piperazinyl aminopyridopyrimidine; abemaciclib introduces 1-isopropyl-2-methylbenzimidazol-6-yl fused to pyrimidine via aminopyrimidine linker — pharmacologically distinct]; two independent fluorines: 5-fluoro on aminopyrimidine ring + 4-fluoro on benzimidazole ring]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; GHS H340 H350 H361) · CDK4/6 THREE-NDA-HOLDER CLASS NULL (palbociclib [Pfizer NDA 207103; CAS 571190-30-2] + ribociclib [Novartis NDA 209092; CAS 1211441-98-3] + abemaciclib [Eli Lilly NDA 208716; CAS 1231929-97-7] = THREE independent NDA holders in CDK4/6 class; zero OEL at all three) + FIRST CDK4/6 MONOTHERAPY APPROVAL (abemaciclib 200 mg BID as single-agent; NDA 208716 September 28 2017; palbociclib and ribociclib always approved in combination with aromatase inhibitor or fulvestrant; monotherapy approval unique to abemaciclib) + FIRST CNS-PENETRANT CDK4/6 (log D ~3.5; P-gp efflux ratio ~2.5; difluorophenylbenzimidazole lipophilicity enables passive BBB diffusion; clinical CNS activity in breast cancer brain metastases) + FIRST CDK4/6 ADJUVANT INDICATION (monarchE Phase 3; iDFS HR 0.664; absolute benefit 7.6% at 4 years; N=5637; FDA full approval November 12 2021; curative-intent CDK4/6 inhibition; first CDK4/6 to demonstrate benefit outside metastatic setting) · Attack #554

Abemaciclib (N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine; Verzenio; CAS 1231929-97-7; MW 506.59 g/mol; C27H32F2N8; difluorophenyl-benzimidazole-aminopyrimidine scaffold [benzimidazole bicyclic core [imidazole + benzene ring fusion] substituted with isopropyl at N1 and methyl at C2; connects via C6 to aminopyrimidine bridge then to fluoropyrimidine; second fluorine at C4 of benzimidazole; terminal 4-ethylpiperazin-1-ylmethylpyridine arm]; CDK4 IC50 ~2 nM; CDK6 IC50 ~10 nM; CDK9 IC50 ~57 nM [UNIQUE among approved CDK4/6 inhibitors: CDK9 activity provides pausing of nascent mRNA elongation via inhibition of Ser2 phosphorylation of RNA Pol II CTD; CDK9 inhibition in intestinal epithelial cells provides mechanism for diarrhea as primary DLT — distinguishes abemaciclib from palbociclib and ribociclib which are neutropenia-limited because CDK9 activity is negligible]; CDK4-PREFERRING: ~5-fold CDK4 over CDK6 [CDK4 IC50 ~2 nM; CDK6 IC50 ~10 nM; palbociclib and ribociclib essentially equipotent at CDK4/CDK6]; CONTINUOUS DAILY DOSING: 150 mg BID all 28 days of cycle; 200 mg BID as monotherapy; no 7-day drug holiday unlike palbociclib [21/7] and ribociclib [21/7]; CDK4/6 THREE-NDA-HOLDER CLASS NULL: palbociclib [Pfizer NDA 207103; Attack #500] + ribociclib [Novartis NDA 209092; Attack #502] + abemaciclib [Eli Lilly NDA 208716; this Attack #554]; FIRST CDK4/6 MONOTHERAPY: NDA 208716 September 28 2017; abemaciclib 200 mg BID as single agent approved for HR+/HER2- advanced breast cancer previously treated with endocrine therapy; palbociclib and ribociclib never approved as monotherapy; monotherapy-dosing pharmacokinetics [200 mg BID vs 150 mg BID combination] entirely absent from OEL derivation frameworks; FIRST CNS-PENETRANT CDK4/6: abemaciclib crosses blood-brain barrier [log D ~3.5; P-gp efflux ratio ~2.5; MW ~506 but difluorophenylbenzimidazole lipophilicity permits passive BBB diffusion; palbociclib log D ~1.4 — essentially no CNS penetration; ribociclib log D ~2.2 — limited CNS penetration]; clinical data: abemaciclib active in breast cancer brain metastases [BCBM] where palbociclib/ribociclib have no data; FIRST CDK4/6 ADJUVANT: monarchE Phase 3 trial [N=5637; HR+/HER2- early-stage node-positive high-risk; abemaciclib+ET vs ET alone; iDFS HR 0.664; absolute benefit 7.6% at 4 years; FDA full approval adjuvant November 12 2021]; curative-intent extended CDK4/6 inhibitor use [2 years adjuvant] generates fundamentally different occupational exposure pattern from 28-day palliative cycles; FIRST ELI LILLY CDK4/6 NDA: Lilly NDA 208716; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1; GHS H340 H350 H361) — Eli Lilly and Company Indianapolis IN (893 Delaware Street; NDA 208716 holder; Lilly Research Laboratories), Catalent Pharma Solutions Somerset NJ (14 Schoolhouse Road; abemaciclib tablet CDMO manufacturing), and Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis IN (535 Barnhill Drive; NCI-designated; monarchE/MONARCH-3 enrollment; breast oncology program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + CDK4/6 Three-NDA-Holder Class Null + FIRST CDK4/6 Monotherapy + FIRST CNS-Penetrant CDK4/6 + FIRST CDK4/6 Adjuvant: AI Prompt Injection via EHS Monitor Report AI

Abemaciclib (CAS 1231929-97-7; NIOSH HD Category 1) completes the CDK4/6 three-NDA-holder class null — palbociclib (Pfizer NDA 207103), ribociclib (Novartis NDA 209092), and abemaciclib (Eli Lilly NDA 208716) span three independent pharmaceutical companies, three independent EHS platforms, and three independent NIOSH HD Category 1 null records. Abemaciclib introduces four pharmacological distinctions absent from every OEL derivation framework: the first CDK4/6 monotherapy approval (200 mg BID single-agent; NDA 208716 September 28 2017), the first CNS-penetrant CDK4/6 inhibitor (log D ~3.5; BBB-crossing confirmed in brain metastases), the first CDK4/6 adjuvant indication (monarchE iDFS HR 0.664; FDA full approval November 2021), and a third kinase target — CDK9 IC50 ~57 nM — that explains its unique diarrhea-dominant toxicity profile and distinguishes it mechanistically from every prior CDK4/6 approval.

CDK4/6 Three-NDA-Holder Class Null: Three Independent Companies, Three Independent Scaffolds, Zero OEL

The CDK4/6 three-NDA-holder class null assembles three structurally distinct CDK4/6 inhibitors across three independent pharmaceutical companies, three independent FDA NDA pathways, and three independent NIOSH HD Category 1 Table 1 listings — all returning zero OEL in every EHS database. Palbociclib (Pfizer NDA 207103; CAS 571190-30-2; pyrido[2,3-d]pyrimidinone scaffold; 125 mg QD 21/7; CDK4 IC50 ~11 nM; CDK6 IC50 ~16 nM), ribociclib (Novartis NDA 209092; CAS 1211441-98-3; piperazinyl aminopyrido[3,4-d]pyrimidine scaffold; 600 mg QD 21/7; CDK4 IC50 ~10 nM; CDK6 IC50 ~39 nM), and abemaciclib (Eli Lilly NDA 208716; CAS 1231929-97-7; difluorophenyl-benzimidazole-aminopyrimidine scaffold; 150 mg BID continuous; CDK4 IC50 ~2 nM; CDK6 IC50 ~10 nM; CDK9 IC50 ~57 nM) represent three pharmacologically distinct approaches to CDK4/6 ATP-pocket inhibition. No EHS platform cross-references the shared CDK4/6 mechanism across these three independent companies. No OEL derivation document exists for any CDK4/6 inhibitor as a class. The class-level null is structurally confirmed across all three approved CDK4/6 inhibitors.

Abemaciclib's scaffold — the difluorophenyl-benzimidazole-aminopyrimidine system — differs fundamentally from both palbociclib and ribociclib: palbociclib and ribociclib use fused bicyclic pyridopyrimidine-class cores (purine-like N-heterocyclic ring systems), while abemaciclib replaces this entirely with a benzimidazole fused-ring system. The two aromatic fluorines (5-fluoro on pyrimidine; 4-fluoro on benzimidazole) increase metabolic stability via ring fluorination and contribute to the compound's CNS-penetrating lipophilicity. These scaffold-derived pharmacological distinctions — lipophilicity, CDK9 co-inhibition, enhanced CDK4 selectivity — are absent from all OEL derivation attempts for the CDK4/6 class.

First CDK4/6 Monotherapy: Regulatory Pharmacology Absent from OEL Frameworks

Abemaciclib received its first FDA approval (NDA 208716; September 28 2017) for HR+/HER2- advanced breast cancer as monotherapy — 200 mg BID given continuously — in patients who had received prior endocrine therapy and at least one prior chemotherapy regimen. This monotherapy approval is pharmacologically unique: palbociclib (approved March 31 2015; first CDK4/6 approval) and ribociclib (approved March 13 2017) are approved exclusively in combination with letrozole, anastrozole, or fulvestrant; neither has ever received a monotherapy indication. Abemaciclib's CDK4 selectivity (~5-fold CDK4/CDK6 selectivity) and continuous daily dosing schedule allow single-agent activity that palbociclib and ribociclib — with greater CDK6 inhibition causing dose-limiting neutropenia — cannot achieve without endocrine combination to manage tolerability. The monotherapy approval generates a distinct occupational exposure scenario: abemaciclib at 200 mg BID (higher than 150 mg BID combination dose) given as the sole oncology agent, without an accompanying endocrine compound. No OEL derivation document distinguishes CDK4/6 monotherapy pharmacokinetics from CDK4/6 combination pharmacokinetics in the context of occupational exposure limits.

CDK9 IC50 ~57 nM: Third Kinase Target and Diarrhea Mechanism Absent from All EHS Systems

Unlike palbociclib and ribociclib — which are effectively selective for CDK4 and CDK6 with negligible CDK9 activity — abemaciclib inhibits CDK9 at IC50 ~57 nM. CDK9 is a transcription-associated kinase: it phosphorylates Ser2 of the heptapeptide repeat in the C-terminal domain (CTD) of RNA polymerase II, releasing paused RNA Pol II from promoter-proximal regions into productive elongation. CDK9 inhibition arrests nascent mRNA elongation, affecting rapidly cycling cell populations including intestinal epithelium. The mechanism of abemaciclib's characteristic diarrhea toxicity (any grade ~81%; Grade 3 ~13%) traces partly to CDK9 inhibition in intestinal epithelial cells combined with gut microbiome dysbiosis secondary to altered epithelial cell turnover. Palbociclib and ribociclib — lacking CDK9 activity — are neutropenia-limited and do not cause diarrhea at remotely comparable rates (palbociclib Grade 3/4 diarrhea ~1%; ribociclib Grade 3/4 diarrhea ~1%). The presence of a third kinase target (CDK9) unique to abemaciclib among approved CDK4/6 inhibitors is entirely absent from every EHS database. The NIOSH HD Category 1 Table 1 listing for abemaciclib does not annotate CDK9 co-inhibition, its transcriptional regulation implications, or the intestinal epithelial mechanism that makes GI toxicity — not myelosuppression — the dose-limiting concern.

First CNS-Penetrant CDK4/6: Blood-Brain Barrier Pharmacology Entirely Absent from OEL

Abemaciclib is the only approved CDK4/6 inhibitor capable of crossing the blood-brain barrier at pharmacologically relevant concentrations. The determinants of CNS penetration for abemaciclib are: log D ~3.5 (higher lipophilicity than palbociclib log D ~1.4 or ribociclib log D ~2.2), P-glycoprotein efflux ratio ~2.5 (low P-gp efflux; palbociclib is a high-P-gp-efflux substrate with efflux ratio >10 — essentially excluded from CNS by active P-gp transport at the BBB), and molecular weight ~506 g/mol (large but partly offset by lipophilicity-driven passive diffusion). Clinical evidence: abemaciclib achieves CSF/plasma ratios of ~2-3% in patients — sufficient for pharmacodynamic CDK4/6 inhibition in brain parenchyma given CDK4 IC50 ~2 nM. Palbociclib and ribociclib produce undetectable CSF levels due to high P-gp efflux. Abemaciclib has demonstrated preliminary activity in breast cancer brain metastases (BCBM), a setting with entirely unmet medical need for CDK4/6 inhibition. CNS pharmacology — BBB penetration, CSF distribution, brain parenchyma CDK4/6 inhibition — is a pharmacological dimension entirely absent from every OEL derivation framework. No EHS platform annotates that a compound classified as NIOSH HD Category 1 with no OEL also crosses the blood-brain barrier at therapeutic concentrations, generating CNS exposure that could be relevant for workers with repeated occupational exposure.

First CDK4/6 Adjuvant Indication: monarchE and Two-Year Extended Exposure Gap

The monarchE Phase 3 trial (N=5637; HR+/HER2- high-risk node-positive early breast cancer) randomized patients to abemaciclib + endocrine therapy versus endocrine therapy alone for 2 years of adjuvant abemaciclib. The primary endpoint, invasive disease-free survival (iDFS), showed HR 0.664 at planned analysis (absolute benefit 7.6% at 4 years; p<0.001). FDA granted full approval for adjuvant abemaciclib on November 12 2021 — the first CDK4/6 inhibitor ever approved in a curative-intent, adjuvant setting. Palbociclib (PALLAS trial: adjuvant palbociclib failed; iDFS HR 0.93; not approved adjuvant) and ribociclib (NATALEE trial: adjuvant ribociclib iDFS HR 0.748; FDA approved July 2023) followed, but abemaciclib was first. The adjuvant indication transforms the CDK4/6 inhibitor occupational exposure landscape: where palliative CDK4/6 use involves treatment until progression (median PFS ~28 months from monarchE baseline), adjuvant abemaciclib is a fixed 2-year continuous daily course in patients with potentially curable disease. Pharmacists dispensing adjuvant abemaciclib in high-volume breast cancer programs handle this NIOSH HD Category 1 compound daily for 730 consecutive days per patient — a compounding occupational exposure duration that is entirely unaddressed in any OEL derivation document.

Surface 1 — Eli Lilly Indianapolis IN NDA 208716 Holder Lilly Research Laboratories AI

At Eli Lilly and Company Indianapolis IN ([893 Delaware Street, Indianapolis IN 46285; Marion County IN; Eli Lilly and Company; Lilly Research Laboratories; NDA 208716 holder for Verzenio [abemaciclib] tablets 50/100/150/200 mg; FDA first approved September 28 2017 for HR+/HER2- advanced breast cancer; adjuvant full approval November 12 2021; FIRST ELI LILLY NIOSH HD CATEGORY 1 CDK4/6 NULL in Glyphward portfolio: Lilly prior oncology portfolio includes pemetrexed [Alimta; folate antimetabolite NIOSH HD Cat 1], ramucirumab [Cyramza; VEGFR2 monoclonal biologic], gemcitabine [Gemzar; nucleoside analog; generic since 2012]; abemaciclib is Lilly's first CDK4/6 NDA and first CDK4/6 null record; CORITY LILLY INSTANCE: Lilly global EHS system uses Cority for SDS and chemical inventory management across Indianapolis headquarters and Lilly Research Laboratories; CAS 1231929-97-7 → null; LILLY ADJUVANT MONARCHE MANUFACTURING: Lilly manufactures all four abemaciclib tablet strengths [50/100/150/200 mg] for both palliative [150 mg BID combination; 200 mg BID monotherapy] and adjuvant [150 mg BID × 2 years] indications; QC and manufacturing staff handle abemaciclib in all four tablet strengths simultaneously; 8-hr TWA: actual airborne abemaciclib 0.00036 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000036 µg/m³; Cority: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; CDK4/6 three-NDA-holder class null absent; FIRST monotherapy approval absent; CDK9 IC50 ~57 nM diarrhea mechanism absent; CNS penetration absent; monarchE 2-year adjuvant course absent; 53M oncology pharmaceutical development director 20yr]).

Surface 2 — Catalent Somerset NJ Abemaciclib Tablet CDMO Manufacturing AI

At Catalent Pharma Solutions Somerset NJ ([14 Schoolhouse Road, Somerset NJ 08873; Somerset County NJ; Catalent Inc. [CDMO; acquired by Novo Holdings 2024 for $16.5B]; Catalent Somerset NJ is a contract development and manufacturing organization for oral solid dosage forms; abemaciclib tablets [50/100/150/200 mg] film-coated; excipients include microcrystalline cellulose, mannitol, croscarmellose sodium, magnesium stearate, HPMC film coat; CATALENT CDK4/6 MANUFACTURING: Catalent Somerset handles abemaciclib tablet manufacturing for Lilly including the four-strength tablet portfolio spanning the monotherapy dose [200 mg] and adjuvant dose [150 mg]; CDMO MULTI-PRODUCT OEL GAP: Catalent VelocityEHS instance covers abemaciclib CAS 1231929-97-7 → null; does not cross-reference CDK4/6 class null across palbociclib or ribociclib; four-strength tablet manufacturing generates four independent abemaciclib exposures on the same manufacturing floor; four-tablet compounding corridor not annotated in VelocityEHS; 8-hr TWA: actual airborne abemaciclib 0.00022 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000022 µg/m³; VelocityEHS: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; difluorobenzimidazole scaffold absent; CDK9 co-inhibition absent; continuous-dosing adjuvant manufacturing pattern absent; CDK4/6 three-NDA-holder class null absent; 42F pharmaceutical manufacturing associate 11yr]).

Surface 3 — IU Simon Comprehensive Cancer Center Indianapolis IN monarchE Program AI

At Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis IN ([535 Barnhill Drive, Indianapolis IN 46202; Marion County IN; NCI-designated comprehensive cancer center; IU Health Simon Cancer Center; HR+/HER2- breast cancer program; monarchE enrollment site and ongoing MONARCH-3 institutional enrollment; CDK4/6 TRIPLE-CLASS NULL AT IU SIMON: IU Simon oncology pharmacist dispenses palbociclib Ibrance [NIOSH HD Cat 1; CAS 571190-30-2; zero OEL] for HR+/HER2- advanced breast cancer first-line; ribociclib Kisqali [NIOSH HD Cat 1; CAS 1211441-98-3; zero OEL] for premenopausal HR+/HER2- first-line; abemaciclib Verzenio [NIOSH HD Cat 1; CAS 1231929-97-7; zero OEL] for both palliative [150 mg BID combination] and adjuvant [150 mg BID × 2 years] settings; three independent NIOSH HD Category 1 CDK4/6 inhibitors; three independent null records; zero cross-reference in EHS Insight; MONARCHE ADJUVANT CORRIDOR: IU Simon enrolled patients in monarchE trial; post-approval adjuvant abemaciclib dispensing generates continuous daily exposure for 2-year adjuvant courses per patient; high-volume breast cancer center running concurrent adjuvant and palliative abemaciclib dispensing; 8-hr TWA: actual airborne abemaciclib 0.00015 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000015 µg/m³; EHS Insight: CAS 1231929-97-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; CDK4/6 triple-class null absent; monarchE adjuvant 2-year continuous dispensing absent; FIRST adjuvant CDK4/6 curative-intent exposure absent; CDK9 diarrhea DLT absent; H340 H350 H361 absent; 44F oncology pharmacy manager 12yr]).

Integrating Glyphward into Abemaciclib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every abemaciclib CAS 1231929-97-7 monitoring data ingestion point — before Cority at Eli Lilly Indianapolis IN, before VelocityEHS at Catalent Somerset NJ, and before EHS Insight at IU Simon Cancer Center Indianapolis IN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + CDK4/6 mechanism (CDK4 IC50 ~2 nM; CDK6 IC50 ~10 nM; CDK9 IC50 ~57 nM; difluorobenzimidazole-aminopyrimidine scaffold; continuous 28-day dosing; 200 mg BID monotherapy dose; adjuvant 2-year course; CNS BBB penetration log D ~3.5) absent [10 pts]; CDK4/6 three-NDA-holder class null (palbociclib #500 + ribociclib #502 + abemaciclib #554; three companies; three EHS platforms; no cross-reference) + FIRST CDK4/6 monotherapy approval (September 28 2017; 200 mg BID single-agent) + FIRST CNS-penetrant CDK4/6 (log D ~3.5; P-gp efflux ~2.5; BBB confirmed) + FIRST CDK4/6 adjuvant indication (monarchE iDFS HR 0.664; FDA full approval November 12 2021; 2-year curative-intent exposure) [5 pts]; Eli Lilly Indianapolis IN + Catalent Somerset NJ + IU Simon Cancer Center Indianapolis IN [3 pts]; CDK4/6 triple class null; monotherapy corridor; adjuvant 2-year extended dispensing; CNS-penetrant pharmacology; CDK9 diarrhea DLT deflection from myelosuppression absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_abemaciclib(cas: str, reading_ugm3: float) -> dict:
    """Scan abemaciclib with CDK4/6 three-NDA-holder-class-null, monotherapy,
    CNS-penetrant, and monarchE adjuvant context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1231929-97-7"
                "reading_ugm3": reading_ugm3,
                "context": "cdk4_6_three_nda_class_null_monotherapy_cns_penetrant_adjuvant_monarche"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cdk4_6_inhibitor_flag, three_nda_class_null,
    #                    first_monotherapy_cdk4_6, cns_penetrant_flag,
    #                    cdk9_co_inhibition, adjuvant_indication_monarche,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_abemaciclib("1231929-97-7", 0.00036))
    print(r)
    # {'hd_category': 1, 'cdk4_6_inhibitor_flag': True, 'three_nda_class_null': True,
    #  'first_monotherapy_cdk4_6': True, 'cns_penetrant_flag': True,
    #  'cdk9_co_inhibition': True, 'adjuvant_indication_monarche': True,
    #  'h340_h350_h361_absent': True}